CYTK
CYTK
NASDAQ · Biotechnology

Cytokinetics Inc

$67.59
+0.03 (+0.04%)
As of Sep 22, 9:48 PM ET ·
Financial Highlights (FY 2026)
Revenue
102.81M
Net Income
-916,673,735
Gross Margin
Profit Margin
-891.6%
Rev Growth
-2.4%
D/E Ratio
0.59
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 41.7% 41.7%
Operating Margin -833.2% -749.8% 29.1% 29.0%
Profit Margin -891.6% -847.0% 18.4% 22.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 102.81M 105.30M 617.31M 631.19M
Gross Profit 257.41M 263.20M
Operating Income -856,554,624 -789,612,989 179.75M 183.04M
Net Income -916,673,735 -845,033,659 113.32M 141.95M
Gross Margin 41.7% 41.7%
Operating Margin -833.2% -749.8% 29.1% 29.0%
Profit Margin -891.6% -847.0% 18.4% 22.5%
Rev Growth -2.4% -2.4% +3.9% +23.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.79B 1.79B 602.04M 772.62M
Total Equity 3.03B 3.03B 2.97B 3.11B
D/E Ratio 0.59 0.59 0.20 0.25
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -844,764,280 -822,007,647 314.99M 272.50M
Free Cash Flow 143.60M 140.08M